Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
Indexed in
Identification of Peptides for Immunotherapy of Cancer. It is Still Worth the Effort
ABSTRACT
As the nature of the T cell immune response is defined by T cell receptor recognition of small protein fragments, referred to as peptides, the identification of peptides would lead us to understanding and directing the T-cell-mediated immune response. Immunogenic peptides might be used for vaccination and activation of the immune reaction against cancer- and virus-infected cells. Additionally, the knowledge of immunogenic peptides was expected to lead to blocking of allergic reactions and autoimmune diseases. Based on these assumptions, the search for immunogenic peptides was started in mice and man in the mid-1980s. After a decade of peptide identification and testing in vitro and in vivo, this may be a proper time to evaluate the results from the peptide-related work and determine the possible applications of this knowledge for the next decade. In this review we discuss the identification of peptides, their use in murine models, as well as clinical data from peptide vaccinations or therapies. Potential hazards and limitations of peptide use in immunotherapy and other possible applications for peptides or peptide motifs in immunotherapy are evaluated.
-
Nieland John D., Da Silva Diane M., Velders Markwin P., de Visser Karin E., Schiller John T., M�ller Martin, Kast W. Martin, Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response, Journal of Cellular Biochemistry, 73, 2, 1999. Crossref
-
Kanodia Shreya, Kast W Martin, Peptide-based vaccines for cancer: realizing their potential, Expert Review of Vaccines, 7, 10, 2008. Crossref
-
Ge Hai-Liang, Wang Ying, Wang Shu-Jun, Zhang Yong, Identification of Melanoma-specific Peptide Epitopes by HLA-A2.1-restricted Cytotoxic T Lymphocytes, Acta Biochimica et Biophysica Sinica, 38, 2, 2006. Crossref
-
Ghim S.-J., Sundberg J., Delgado G., Jenson A.B., The Pathogenesis of Advanced Cervical Cancer Provides the Basis for an Empirical Therapeutic Vaccine, Experimental and Molecular Pathology, 71, 3, 2001. Crossref
-
Svane IM, Boesen M, Engel A-M, The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors— lessons from normal and immunodeficient mice, Medical Oncology, 16, 4, 1999. Crossref
-
Ingram S.B., O’Rourke M.G., DC therapy for metastatic melanoma, Cytotherapy, 6, 2, 2004. Crossref
-
Schoell Wolfgang M.J., Mirhashemi Ramin, Liu Bai, Janicek Mike F., Podack Eckhard R., Penalver Manuel A., Averette Hervy E., Generation of Tumor-Specific Cytotoxic T Lymphocytes by Stimulation with HPV Type 16 E7 Peptide-Pulsed Dendritic Cells: An Approach to Immunotherapy of Cervical Cancer, Gynecologic Oncology, 74, 3, 1999. Crossref
-
Pietersz Geoffrey A, Li Wenjun, Apostolopoulos Vasso, A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway, Vaccine, 19, 11-12, 2001. Crossref
-
Chen Lieping, Mimotopes of cytolytic T lymphocytes in cancer immunotherapy, Current Opinion in Immunology, 11, 2, 1999. Crossref
-
Da Silva Diane M., Eiben Gretchen L., Fausch Steven C., Wakabayashi Mark T., Rudolf Michael P., Velders Markwin P., Kast W. Martin, Cervical cancer vaccines: Emerging concepts and developments, Journal of Cellular Physiology, 186, 2, 2001. Crossref
-
Johnson Aaron J., Mendez-Fernandez Yanice, Moyer Ann M., Sloma Cari R., Pirko Istvan, Block Matthew S., Rodriguez Moses, Pease Larry R., Antigen-Specific CD8+T Cells Mediate a Peptide-Induced Fatal Syndrome, The Journal of Immunology, 174, 11, 2005. Crossref
-
Lo-Man Richard, Vichier-Guerre Sophie, Bay Sylvie, Dériaud Edith, Cantacuzène Danièle, Leclerc Claude, Anti-Tumor Immunity Provided by a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri-Tn Glycotope, The Journal of Immunology, 166, 4, 2001. Crossref
-
O'Rourke Michael G. E., Johnson Maree, Lanagan Catherine, See Janet, Yang Jie, Bell John R., Slater Greg J., Kerr Beverley M., Crowe Beth, Purdie David M., Elliott Suzanne L., Ellem Kay A. O., Schmidt Christopher W., Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine, Cancer Immunology, Immunotherapy, 52, 6, 2003. Crossref
-
Harmala Lisa A. E., Ingulli Elizabeth G., Curtsinger Julie M., Lucido Michelle M., Schmidt Clint S., Weigel Brenda J., Blazar Bruce R., Mescher Matthew F., Pennell Christopher A., The Adjuvant Effects of Mycobacterium tuberculosis Heat Shock Protein 70 Result from the Rapid and Prolonged Activation of Antigen-Specific CD8+ T Cells In Vivo, The Journal of Immunology, 169, 10, 2002. Crossref
-
Johnson Aaron J., Upshaw Jadee, Pavelko Kevin D., Rodriguez Moses, Pease Larry R., Preservation of motor function by inhibition of CD8+ virus peptide‐specific T cells in Theiler's virus infection, The FASEB Journal, 15, 14, 2001. Crossref